Realizing that all LKB1-mutated cell lines in this panel also harbored activating KRAS mutations (Table 2) we hypothesized that these alterations could impede, in some way, Birinapant action and justify the resistance of LKB1-mutated NSCLC cell lines. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.